Titre : Interleukine-9

Interleukine-9 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Methicillin-Resistant Staphylococcus aureus
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Interleukine-9 : Questions médicales les plus fréquentes", "headline": "Interleukine-9 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Interleukine-9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-04", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Interleukine-9" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Interleukines", "url": "https://questionsmedicales.fr/mesh/D007378", "about": { "@type": "MedicalCondition", "name": "Interleukines", "code": { "@type": "MedicalCode", "code": "D007378", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.465" } } }, "about": { "@type": "MedicalCondition", "name": "Interleukine-9", "alternateName": "Interleukin-9", "code": { "@type": "MedicalCode", "code": "D016906", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sushmita Chakraborty", "url": "https://questionsmedicales.fr/author/Sushmita%20Chakraborty", "affiliation": { "@type": "Organization", "name": "Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110029, India." } }, { "@type": "Person", "name": "Dipendra Kumar Mitra", "url": "https://questionsmedicales.fr/author/Dipendra%20Kumar%20Mitra", "affiliation": { "@type": "Organization", "name": "Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110029, India." } }, { "@type": "Person", "name": "Mattia Matasci", "url": "https://questionsmedicales.fr/author/Mattia%20Matasci", "affiliation": { "@type": "Organization", "name": "Philochem AG, CH-8112 Otelfingen, Switzerland." } }, { "@type": "Person", "name": "Dario Neri", "url": "https://questionsmedicales.fr/author/Dario%20Neri", "affiliation": { "@type": "Organization", "name": "Philochem AG, CH-8112 Otelfingen, Switzerland." } }, { "@type": "Person", "name": "Katharina F Kubatzky", "url": "https://questionsmedicales.fr/author/Katharina%20F%20Kubatzky", "affiliation": { "@type": "Organization", "name": "Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "LYZ2-SH3b as a novel and efficient enzybiotic against methicillin-resistant Staphylococcus aureus.", "datePublished": "2023-09-13", "url": "https://questionsmedicales.fr/article/37704938", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12866-023-03002-9" } }, { "@type": "ScholarlyArticle", "name": "Capillary electrophoretic methods for classification of methicillin-resistant Staphylococcus aureus (MRSA) clones.", "datePublished": "2022-08-31", "url": "https://questionsmedicales.fr/article/36089316", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.aca.2022.340305" } }, { "@type": "ScholarlyArticle", "name": "Relationship between mortality and molecular epidemiology of methicillin-resistant Staphylococcus aureus bacteremia.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35802589", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0271115" } }, { "@type": "ScholarlyArticle", "name": "Engineering a \"detect and destroy\" skin probiotic to combat methicillin-resistant Staphylococcus aureus.", "datePublished": "2022-12-15", "url": "https://questionsmedicales.fr/article/36520793", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0276795" } }, { "@type": "ScholarlyArticle", "name": "Proton Motive Force Inhibitors Are Detrimental to Methicillin-Resistant Staphylococcus aureus Strains.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35943153", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1128/spectrum.02024-22" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Interleukines", "item": "https://questionsmedicales.fr/mesh/D007378" }, { "@type": "ListItem", "position": 6, "name": "Interleukine-9", "item": "https://questionsmedicales.fr/mesh/D016906" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Interleukine-9 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Interleukine-9", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Interleukine-9", "description": "Comment mesurer l'interleukine-9 ?\nQuels tests sont utilisés pour le diagnostic ?\nL'IL-9 est-elle liée à des maladies spécifiques ?\nQuels biomarqueurs sont associés à l'IL-9 ?\nL'IL-9 peut-elle être un indicateur de gravité ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Interleukine-9", "description": "Quels symptômes sont liés à l'IL-9 ?\nL'IL-9 provoque-t-elle des symptômes respiratoires ?\nY a-t-il des symptômes cutanés associés ?\nL'IL-9 est-elle liée à des symptômes gastro-intestinaux ?\nQuels signes cliniques sont observés ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Interleukine-9", "description": "Comment prévenir les maladies liées à l'IL-9 ?\nY a-t-il des vaccins pour l'IL-9 ?\nL'éducation des patients est-elle importante ?\nLes changements alimentaires peuvent-ils aider ?\nLe contrôle de l'environnement est-il crucial ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Interleukine-9", "description": "Comment traiter les niveaux élevés d'IL-9 ?\nY a-t-il des thérapies ciblées pour l'IL-9 ?\nLes corticostéroïdes affectent-ils l'IL-9 ?\nQuels médicaments sont utilisés pour l'asthme lié à l'IL-9 ?\nL'immunothérapie aide-t-elle avec l'IL-9 ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Interleukine-9", "description": "Quelles complications peuvent survenir avec l'IL-9 ?\nL'IL-9 peut-elle aggraver d'autres maladies ?\nY a-t-il des risques de surinfection ?\nDes complications pulmonaires sont-elles possibles ?\nL'IL-9 est-elle liée à des troubles cardiovasculaires ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Interleukine-9", "description": "Quels sont les facteurs de risque pour l'IL-9 ?\nL'exposition à la pollution augmente-t-elle le risque ?\nLe tabagisme influence-t-il l'IL-9 ?\nLes infections respiratoires sont-elles un facteur ?\nLe stress a-t-il un impact sur l'IL-9 ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Methicillin-Resistant+Staphylococcus+aureus&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer l'interleukine-9 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-9 peut être mesurée par des tests ELISA dans le sérum ou les fluides biologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses de cytokines sont utilisés pour évaluer l'IL-9." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 est associée à des maladies comme l'asthme et certaines allergies." } }, { "@type": "Question", "name": "Quels biomarqueurs sont associés à l'IL-9 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-9 est souvent mesurée avec d'autres cytokines comme l'IL-4 et l'IL-5." } }, { "@type": "Question", "name": "L'IL-9 peut-elle être un indicateur de gravité ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés d'IL-9 peuvent indiquer une inflammation sévère." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'IL-9 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des réactions allergiques, de l'asthme et des inflammations." } }, { "@type": "Question", "name": "L'IL-9 provoque-t-elle des symptômes respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 est impliquée dans l'hyperréactivité bronchique et l'asthme." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées peuvent survenir dans des conditions allergiques liées à l'IL-9." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des symptômes gastro-intestinaux ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut être impliquée dans des troubles gastro-intestinaux allergiques." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des difficultés respiratoires, des éruptions cutanées et des démangeaisons." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées à l'IL-9 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les allergènes et adopter un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des vaccins pour l'IL-9 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour cibler l'IL-9." } }, { "@type": "Question", "name": "L'éducation des patients est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer les patients sur les déclencheurs allergiques est essentiel pour la prévention." } }, { "@type": "Question", "name": "Les changements alimentaires peuvent-ils aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut aider à réduire l'inflammation et les symptômes." } }, { "@type": "Question", "name": "Le contrôle de l'environnement est-il crucial ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, réduire l'exposition aux allergènes environnementaux est essentiel pour la prévention." } }, { "@type": "Question", "name": "Comment traiter les niveaux élevés d'IL-9 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements anti-inflammatoires et des antihistaminiques peuvent être utilisés." } }, { "@type": "Question", "name": "Y a-t-il des thérapies ciblées pour l'IL-9 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anticorps monoclonaux ciblant l'IL-9 sont en développement pour traiter l'asthme." } }, { "@type": "Question", "name": "Les corticostéroïdes affectent-ils l'IL-9 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent réduire les niveaux d'IL-9 et l'inflammation associée." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour l'asthme lié à l'IL-9 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les bronchodilatateurs et les corticostéroïdes sont couramment prescrits." } }, { "@type": "Question", "name": "L'immunothérapie aide-t-elle avec l'IL-9 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'immunothérapie peut aider à moduler la réponse immunitaire liée à l'IL-9." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'IL-9 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des exacerbations d'asthme et des réactions allergiques sévères." } }, { "@type": "Question", "name": "L'IL-9 peut-elle aggraver d'autres maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut exacerber des maladies auto-immunes et inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des risques de surinfection ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des niveaux élevés d'IL-9 peuvent être à risque de surinfections." } }, { "@type": "Question", "name": "Des complications pulmonaires sont-elles possibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut contribuer à des complications pulmonaires comme la fibrose." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des troubles cardiovasculaires ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre l'IL-9 et des troubles cardiovasculaires, mais c'est encore à étudier." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'IL-9 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux d'allergies et d'asthme augmentent le risque d'IL-9 élevée." } }, { "@type": "Question", "name": "L'exposition à la pollution augmente-t-elle le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la pollution de l'air est un facteur de risque connu pour les maladies liées à l'IL-9." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il l'IL-9 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter les niveaux d'IL-9 et aggraver les symptômes respiratoires." } }, { "@type": "Question", "name": "Les infections respiratoires sont-elles un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections respiratoires peuvent déclencher une réponse immunitaire impliquant l'IL-9." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur l'IL-9 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut exacerber les symptômes et augmenter les niveaux d'IL-9." } } ] } ] }

Sources (10000 au total)

LYZ2-SH3b as a novel and efficient enzybiotic against methicillin-resistant Staphylococcus aureus.

Enzybiotics are promising alternatives to conventional antibiotics for drug-resistant infections. Exolysins, as a class of enzybiotics, show antibacterial effects against methicillin-resistant Staphyl... This study designed a chimeric exolysin by fusing the Cell-binding domain (SH3b) from Lysostaphin with the lytic domain (LYZ2) from the gp61 enzyme. Subsequently, LYZ2-SH3b was cloned and expressed in... Analysis of bioinformatics showed that LYZ2-SH3b was stable, soluble, and non-allergenic. Protein purification was performed with a 0.8 mg/ml yield for LYZ2-SH3b. The plate lysis assay results indicat... The study suggests that phage endolysins, such as LYZ2-SH3b, may represent a promising new approach to treating MRSA infections, particularly in cases where antibiotic resistance is a concern. But fur...

Pediatric Utilization of Methicillin-resistant Staphylococcus aureus Nasal Swabs for Antimicrobial Stewardship.

Methicillin-resistant Staphylococcus aureus (MRSA) can cause serious infections and empiric treatment regimens in children frequently include an anti-MRSA antibiotic. Studies in adults have demonstrat... This was a single-site, retrospective cohort study of pediatric patients admitted with a suspected infectious diagnosis who had an MNS performed during their hospitalization between June 1, 2018 and N... This study identified 172 patients who met the inclusion criteria. Eleven (6.4%) nasal swabs were positive for MRSA and 10 (5.8%) microbiological cultures from suspected sources of infection were iden... MNS has a high NPV and low PPV in children. MNS can be utilized as an antimicrobial stewardship tool to guide the safe de-escalation of anti-MRSA antibiotics in children....

Methicillin-Resistant Staphylococcus aureus Pneumatoceles in a Neonate With Sotos Syndrome : A Case Report.

Necrotizing pneumonia caused by methicillin-resistant Staphylococcus aureus can lead to the formation of pneumatoceles in the lungs. Standard treatment guidelines are not available due to the rarity o... Baby H. required prolonged respiratory support and supplemental oxygen to maintain appropriate oxygen saturation parameters for infants more than 34 weeks' gestation corrected. He was found to have mu... Baby H. was a former 32.2-week gestation male infant diagnosed with pneumonia caused by necrotizing methicillin-resistant Staphylococcus aureus leading to pneumatocele formation in both lungs.... Baby H. was managed with aggressive antibiotic therapy and then was conservatively managed until he received a tracheostomy tube on day of life (DOL) 75 to prepare for discharge home.... Baby H. was discharged from the neonatal intensive care unit (NICU) on DOL 113 with a tracheostomy tube for prolonged mechanical ventilatory support and a gastrostomy tube for nutrition. Numerous foll... While methicillin-resistant Staphylococcus aureus pneumatoceles are uncommon in the NICU setting, it is important for neonatal care providers to be aware of the causes and treatment choices currently ...

Biofilm-producing ability of methicillin-resistant Staphylococcus aureus clinically isolated in China.

Staphylococcus aureus, a commensal bacterium, colonizes the skin and mucous membranes of approximately 30% of the human population. Apart from conventional resistance mechanisms, one of the pathogenic... Analyzing non-repetitive clinical isolates of MRSA collected from seven provinces and cities in China between 2014 and 2020, it was observed that 53.2% of the MRSA isolates exhibited varying degrees o... MRSA strains with biofilm production capability warrant increased vigilance....

Markers of epidemiological success of methicillin-resistant Staphylococcus aureus isolates in European populations.

Methicillin-resistant Staphylococcus aureus (MRSA) infections impose a considerable burden on health systems, yet there is remarkable variation in the global incidence and epidemiology of MRSA. The MA... Operational definitions of success were defined in consortium meetings to compose a balanced strain collection of successful and sporadic MRSA isolates. Isolates were subjected to antimicrobial suscep... Heterogeneity of MRSA isolate collections across countries hampered the use of a unified operational definition of success; therefore, country-specific approaches were used to establish the MACOTRA st... Our results are the strongest yet to associate MRSA antibiotic resistance profiles and antibiotic usage with the incidence of infection and successful clonal spread, which varied by country. Harmonize...